Levetiracetam is one of the new anticonvulsant drugs that has a high therapeutic index and potential antiepileptogenic effects. Herein, we report a patient with multidrug refractory epilepsy and Ohtahara syndrome who was accidentally administered 300 mg/kg/d for 35 days by her mother. To our knowledge, there are only a few cases of accidental overdose of levetiracetam in pediatric patients reported in the literature, and this case study is the first to report such a high and long-term dose in an infant who showed no adverse effects.
GorayaJSKhuranaDSValenciaI, et al.Intravenous levetiracetam in children with epilepsy. Pediatr Neurol. 2008;38:177–180.
3.
CilioMRBianchiRBalestriM, et al.Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. Epilepsy Res. 2009;86:66–71.
LiJXiaoNChenS. Efficacy and tolerability of levetiracetam in children with epilepsy. Brain Dev. 2011;33:145–151.
6.
BeranRGBerkovicSFBlackAB, et al.Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 2005;63:1–9.
7.
PatsalosPN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–724.
8.
BodmerMMonteAAKokkoJYinS. Safety of non-therapeutic levetiracetam ingestions—a poison center based study. Pharmacoepidemiol Drug Saf. 2011;20:366–369.
9.
AwaadY. Accidental overdosage of levetiracetam in two children caused no side effects. Epilepsy Behav. 2007;11:247.
10.
GlauserTAPellockJMBebinEM, et al.Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518–524.
11.
BettsTWaegemansTCrawfordP. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80–87.
12.
GrantRShorvonSD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res. 2000;42:89–95.
